Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 22.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 556,454 shares of the biotechnology company's stock after buying an additional 102,195 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.39% of Aurinia Pharmaceuticals worth $4,997,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter worth $25,000. Blue Trust Inc. lifted its position in Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 6,174 shares in the last quarter. FMR LLC lifted its position in shares of Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $108,000. Finally, Bailard Inc. acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $128,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Stock Down 0.6 %
Shares of Aurinia Pharmaceuticals stock traded down $0.05 on Thursday, hitting $8.32. 689,729 shares of the company's stock traded hands, compared to its average volume of 1,334,897. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm's 50-day moving average is $8.01 and its 200 day moving average is $7.96. The stock has a market cap of $1.14 billion, a P/E ratio of -55.46 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67.
Insider Transactions at Aurinia Pharmaceuticals
In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the transaction, the insider now owns 161,789 shares of the company's stock, valued at $1,294,312. The trade was a 7.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $494,872.00. Following the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. This trade represents a 8.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 343,898 shares of company stock valued at $2,753,094. Insiders own 4.30% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 19th.
Check Out Our Latest Report on AUPH
Aurinia Pharmaceuticals Profile
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
